What's Happening?
The Gates Institute, based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant by ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady. This grant aims to develop a modular CAR-T cell manufacturing platform using the G-Rex technology. The funding will support the optimization of manufacturing processes for cell and gene therapy programs, focusing on efficiency and adaptability. The Gates Institute will also gain early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation designed for high-throughput, low-cost production.
AD
Why It's Important?
The grant awarded to the Gates Institute is a significant step in advancing the manufacturing processes for CAR-T cell therapies, which are crucial in treating cancers and rare diseases. The development of a scalable and modular manufacturing platform could lead to more efficient production of these therapies, potentially reducing costs and increasing accessibility for patients. The collaboration between leading organizations in the field underscores the importance of innovation in cell and gene therapy manufacturing, which could accelerate the development and commercialization of life-saving treatments.
What's Next?
The Gates Institute will conduct a structured Design of Experiments (DoE) to optimize key CAR-T cell manufacturing steps, evaluating critical variables to improve product attributes. The institute will continue to offer a broad range of manufacturing options within standardized design spaces for novel therapies. ScaleReady's G-Rex Grant Program will further support the advancement of cell and gene-modified cell therapy development, with additional grant awards and access to exclusive support from consortium partners.
